Pharmaceutisch Weekblad

, Volume 12, Issue 4, pp 121–127 | Cite as

Pharmacokinetics of antimicrobial agents in organ function impairment

A review
  • R. Janknegt


The pharmacokinetics of antimicrobial drugs in various types of organ function impairment are reviewed. The influence of renal function impairment on antimicrobial agents is well-known, although less is known about the accumulation of metabolites during renal failure. Fewer data are available on liver function impairment and more information is needed on highly metabolized agents. Pharmacokinetic studies in severely ill patients are urgently needed to investigate the influence of disease states on pharmacokinetics and to study the possibility of oral administration to seriously ill patients.


Aged Antibiotics Cystic fibrosis Hemodialysis Kidney diseases Liver diseases Peritoneal dialysis, continuous ambulatory Pharmacokinetics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Reed WE, Sabatini S. The use of drugs in renal failure. Semin Nephrol 1986;6:259–95.PubMedGoogle Scholar
  2. 2.
    Davies BI, Maessen FPV. Drug interactions with quinolones. Rev Infect Dis 1989;11(Suppl 5):1083–90.Google Scholar
  3. 3.
    Saivin S, Houin G. Clinical pharmacokinetics of doxycline and minocycline. Clin Pharmacokinet 1988;15:355–66.PubMedGoogle Scholar
  4. 4.
    Reidenberg MM, Drayer DE. Alteration of drug-protein binding in renal disease. Clin Pharmacokinet 1984;9SI:18–26.Google Scholar
  5. 5.
    Janknegt R. Pharmacokinetics of antimicrobial agents in various disease states. Nieuwegein: Glaxo/Bayer (in press).Google Scholar
  6. 6.
    Cockroft DE, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.PubMedGoogle Scholar
  7. 7.
    Robertshaw M, Lai KN, Swaminathan R. Prediction of creatinine clearance from plasma creatinine: comparison of five formulae. Br J Clin Pharmacol 1989;28:275–80.PubMedGoogle Scholar
  8. 8.
    Bennett WM. Guide to drug dosage in renal failure. Clin Pharmacokinet 1988;15:326–54.PubMedGoogle Scholar
  9. 9.
    Reeves DS. The effect of renal failure on the pharmaco-kinetics of antibiotics. J Antimicrob Chemother 1988;21:5–8.PubMedGoogle Scholar
  10. 10.
    Janknegt R. Macrolide antibiotica. I. Overzicht van bacteriologie en farmacokinetiek [Macrolide antibiotics. I. Review of bacteriology and pharmacokinetics]. TGO 1987;12:229–35.Google Scholar
  11. 11.
    Janknegt R. Aminoglycoside antibiotics. Pharm Weekbl [Sci]1990;12:80–90.Google Scholar
  12. 12.
    Roosendaal R. Therapeutic effect of antibiotics in the compromised host, an experimental study [Dissertation]. Rotterdam: Erasmus University Rotterdam, 1988.Google Scholar
  13. 13.
    Lee CC, Marbury TC. Drug therapy in patients undergoing haemodialysis. Clin Pharmacokinet 1984;9:42–66.Google Scholar
  14. 14.
    Choi L, Johnson CA. Dialyzability of drugs. Dial Transplant 1987;16:537–40.Google Scholar
  15. 15.
    Matzke GR, Keane WF. The use of antibiotics in patients with renal insufficiency. In: Petersen PK, Verhoef J, eds. Antimicrobial agents annual 1. Amsterdam: Elsevier Science Publishers, 1986:472–88.Google Scholar
  16. 16.
    Verhoef J, Oe PL, Simonian S. The clearance of antibiotics by the artificial kidney. Chemotherapy 1973;19:272–8.PubMedGoogle Scholar
  17. 17.
    Seyffart G. Drugs in renal failure. Dosing guidelines for frequently used drugs in end-stage renal disease and dialysis patients. Blood Purif 1985;3:140–68.PubMedGoogle Scholar
  18. 18.
    Janknegt R, Koelman JH. Drug therapy in CAPD patients. Pharm Weekbl [Sci] 1987;9:104–9.Google Scholar
  19. 19.
    Janknegt R, Koks CHW. Pharmacokinetic aspects during CAPD. A literature review. Pharm Weekbl [Sci] 1984;6:229–36.Google Scholar
  20. 20.
    Maher JF. Influence of CAPD on elimination of drugs. Perit Dial Bull 1987;7:159–67.Google Scholar
  21. 21.
    Morse GD, Rowinski C, Lieveld PE, Walshe JJ. Drug-protein binding during CAPD. Perit Dial Bull 1986;6:144–7.Google Scholar
  22. 22.
    Janknegt R, Nube MJ. A simple method for predicting drug clearances during CAPD. Perit Dial Bull 1985;5:254–5.Google Scholar
  23. 23.
    Moore R, Smith C, Lietman P. Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides. Am J Med 1986;80:1093–7.PubMedGoogle Scholar
  24. 24.
    Davey PG. Pharmacokinetics in liver disease. J Antimicrob Chemother 1988;21:1–5.Google Scholar
  25. 25.
    Siersema PD, Wilson JHP. Leverziekten en verwerking van geneesmiddelen [Liver disease and drug metabolism]. Geneesmiddelenbulletin 1989;23:26–31.Google Scholar
  26. 26.
    Williams RL. Drug administration in hepatic disease. N Engl J Med 1983;309:1616–22.PubMedGoogle Scholar
  27. 27.
    Pond SM, Tozer NN. First pass elimination. Basic concepts and clinical consequences. Clin Pharmacokinet 1984;9:1–25.Google Scholar
  28. 28.
    Siegers CP, Klaassen CD. Die Bedeutung der biliären Ausscheidung von Pharmaka beim Menschen. Dtsch Med Wochenschr 1983;108:1564–70.PubMedGoogle Scholar
  29. 29.
    Van Dalen R, Vree TB, Baars IM. Influence of protein binding and severity of illness on renal elimination of four cephalosporins in intensive care patients. Pharm Weekbl [Sci] 1987;9:98–103.Google Scholar
  30. 30.
    Bodenham A, Shelly MP, Park GR. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet 1988;14:347–73.PubMedGoogle Scholar
  31. 31.
    Gabriel R. Time to scrap creatinine clearance. Br Med J 1986;293:1119–20.Google Scholar
  32. 32.
    De Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin Pharmacokinet 1987;13:228–53.PubMedGoogle Scholar
  33. 33.
    Norrby SR. Antibiotic therapy in aging patients. Bull NY Acad Med 1987;63:519–32.Google Scholar
  34. 34.
    Ljungberg B, Nilsson-Ehle J. Pharmacokinetics of antimicrobial agents in the elderly. Rev Infect Dis 1987;9:250–62.PubMedGoogle Scholar
  35. 35.
    Ball AP, Fox C, Ball ME, et al. Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients. J Antimicrob Chemother 1986;17:629–35.PubMedGoogle Scholar
  36. 36.
    Wallace SM, Verbeeck RK. Plasma protein binding of drugs in the elderly. Clin Pharmacokinet 1987;12:41–72.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1990

Authors and Affiliations

  • R. Janknegt
    • 1
  1. 1.Department of Clinical PharmacyMaasland HospitalMB Sittardthe Netherlands

Personalised recommendations